A Study to Evaluate the Effect of Ranolazine on Postprandial Glucagon in Subjects With Type 2 Diabetes.
NCT ID: NCT01843127
Last Updated: 2014-03-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
24 participants
INTERVENTIONAL
2013-04-30
2013-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Placebo, Ranolazine, Exenatide
Ranolazine
Placebo
Exenatide
Ranolazine, Placebo, Exenatide
Ranolazine
Placebo
Exenatide
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Ranolazine
Placebo
Exenatide
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documented history of T2DM for ≥5 years
* Body mass index (BMI) 20.0 to 40.0 kg/m2, inclusive, at Screening
* Stable treatment (≥ 12 weeks) with metformin alone, a sulfonylurea alone, a meglitinide alone, or a combination of metformin with either a sulfonylurea or a meglitinide
* HbA1c ≥ 7.0% and ≤ 10.5%, inclusive, at Screening
* Fasting glucose within specific ranges, at Screening and after 14 +/-2 days of wash-out from prior oral anti-diabetic agents
* Fasting serum C-peptide ≥0.8 ng/mL, at Screening
* Estimated glomerular filtration rate (eGFR)≥60 mL/min/1.73 m2
* Ability and willingness to comply with all study procedures during the course of the study, including washout from oral anti-diabetic (OAD) agents approximately 2 weeks prior to Day -2 admission
* Females of childbearing potential must have a negative pregnancy test at Screening and on Day -2 admission and must agree to use highly effective contraception methods from Screening throughout study participation and for 14 days following the last dose of study drug.
Exclusion Criteria
* History of acute diabetes complications
* Recent or significant heart conditions
* Uncontrolled hypertension
* QTc interval \> 500 msec by ECG at Screening or on Day -2 admission, a personal or family history of QTc prolongation, congenital long QT syndrome, or use of drugs that prolong the QTc interval, such as Class Ia or Class III antiarrhythmic agents, erythromycin, and certain antipsychotics (eg, ziprasidone)
* History of severe GI disease (e.g., gastroparesis)
* History of pancreatitis (acute or chronic)
* Current consumption of \> 14 alcoholic drinks per week, or more than 4 alcoholic drinks on any one day
* Current regular use of tobacco- or nicotine-containing products in excess of 10 cigarettes per day or equivalent
* History of substance abuse within 12 months prior to Screening
* Significant hepatic disease, including, but not limited to, chronic active hepatitis and liver cirrhosis (Child-Pugh Class A, B, or C)
* History of malignancy within 5 years prior to Screening
* Significant thyroid disease
* Treatment with selected medications, as indicated in the protocol
* Prior treatment with open-label ranolazine or known hypersensitivity or intolerance to ranolazine or its excipients
* Known hypersensitivity or intolerance to GLP-1 mimetics
* Known hypersensitivity or intolerance to acetaminophen
* Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \> 2.5 X upper limit of normal (ULN)
* Total Bilirubin (TB) \> 2 mg/dL
* Hemoglobin \< 12 g/dL (for males) or \< 11 g/dL (for females)
* Positive for hepatitis B surface antigen
* Positive for anti-hepatitis C virus antibody
* Positive for human immunodeficiency virus-1 (HIV-1) antibody
* Positive urine drug screen
* Positive alcohol test
* Donation of blood or blood products to a blood bank, blood transfusion, or participation in a clinical study requiring withdrawal of \> 500 mL of blood during the 6 weeks prior to Screening
* Females who are pregnant or breastfeeding
* Other condition(s) that, in the opinion of the investigator, would compromise the safety of the subject, would prevent compliance with the study protocol, or would compromise the quality of the clinical study.
18 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gilead Sciences
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Profil Institute for Clinical Research, Inc.
Chula Vista, California, United States
SeaView Research, Inc
Miami, Florida, United States
Translational Research Institute-Florida Hospital
Orlando, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GS-US-259-0165
Identifier Type: -
Identifier Source: org_study_id